Exogene is a biotechnology startup accelerating the discovery of T-cell-receptor(TCR)-based cell therapies for otherwise untreatable solid tumors. They are building a machine learning platform to comprehensively screen TCRs from tumor-infiltrating lymphocytes (TILs) derived from cancer patients to rapidly find new cancer targets and target-specific TCRs for therapeutic application. Using novel wet-lab TCR screening technologies (yeast display combined with mammalian display), Exogene is able to generate data for their machine learning platform in-house by screening billions of TCR-target interactions.